Top 5 Breakthrough Pharmaceutical Drugs of the Decade

  1. Spikevax

  2. Peak Sales Estimate at the Time of Approval (USD Billion): 19

    Disease: COVID-19

    Company: Moderna

    Moderna’s revenue for Q2 2023 was $344 million, down from $4.7 billion in the same quarter last year, reflecting a significant drop in COVID-19 medicine Spikevax sales. Despite the decline, Moderna reported a narrower-than-expected loss and revenue that beat consensus estimates. In Q2 2023 earnings call transcript, CCO Arpa Garay said that company also raised its sales forecast for Spikevax to between $6 billion and $8 billion for the year, up from its previous forecast of $5 billion.